| a |
Original contributions |
| 1. |
Times cited: 201 |
|
Kielstein JT, Böger RH, Bode-Böger SM, Schäffer
J, Barbey M, Koch KM, Frölich JC. Asymmetric dimethylarginine plasma
concentrations differ in patients with end-stage renal disease: relationship
to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999;
10: 594-600.
|
| 2. |
Times cited: 129 |
|
Kielstein JT, Böger RH, Bode-Böger SM,
Frölich JC, Haller H, Ritz E, Fliser D. Marked increase of asymmetric
dimethylarginine in patients with incipient primary chronic renal disease.
J Am Soc Nephrol 2002; 13: 170-176.
|
| 3. |
Times cited: 114 |
|
Kielstein JT, Impraim B, Simmel S, Bode-Böger SM,
Tsikas D, Frölich JC, Hoeper MM, Haller H, Fliser D. Cardiovascular
effects of systemic nitric oxide synthase inhibition with asymmetrical
dimethylarginine in humans. Circulation 2004; 109: 172-177.
|
| 4. |
Times cited: 67 |
|
Kielstein JT, Bode-Böger SM, Frölich JC,
Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine (ADMA), blood pressure
and renal perfusion in elderly subjects. Circulation 2003; 107:
1891-1895.
|
| 5. |
Times cited: 44 |
|
Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr
MJ, Haller H, Fliser D. Efficacy and cardiovascular tolerability of extended
dialysis in critically ill patients: a randomized controlled study. Am
J Kidney Dis 2004; 43: 342-349.
|
| 6. |
Times cited: 32 |
|
Kielstein JT, Bode-Böger SM, Hesse G,
Martens-Lobenhoffer J, Takacs A, Fliser D, Hoeper MM. Asymmetrical
dimethylarginine in idiopathic pulmonary arterial hypertension.
Arterioscler Thromb Vasc Biol 2005; 25: 1414-1418.
|
| b |
Reviews |
| 1. |
Times cited: 46 |
|
Kielstein JT, Zoccali C. Asymmetyric Dimethylarginine:
A cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney
Dis 2005; 46: 186-202..
|
| 2. |
Times cited: 22 |
|
Kielstein JT, Frölich JC, Haller H, Fliser D.
ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating
agent in patients with renal disease? Nephrol Dial Transplant 2001;
16: 1742-1745.
|